Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Person › Details

Oliver Schacht (Curetis AG)

Schacht, Oliver (Curetis 201012– CEO before Epigenomics CFO)


Organisations Organisation Curetis AG
  Today Curetis GmbH
  Group Curetis (Group)
  Former/major organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
Products Product Unyvero molecular diagnostics platform
  Product 2 DNA methylation technology

Curetis AG. (12/15/10). "Press Release: Curetis Appoints Oliver Schacht as CEO". Holzgerlingen.

Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious disease testing, announces
the appointment of Oliver Schacht (current CFO Epigenomics AG / CEO Epigenomics, Inc.) as CEO, effective 1st April 2011.

The supervisory board of Curetis AG has appointed Oliver Schacht, Ph.D. (age 40), who has been serving as a supervisory board member since June 2010, to join the company full time as its CEO.

At Epigenomics, Oliver has proven his ability to build and grow a start-up biotech company into a commercially focused molecular diagnostics enterprise over the past 12 years. He brings a strong background in the global molecular diagnostics industry. His experience includes all aspects of strategic development and implementation, corporate finance and fundraising, product development from discovery of novel biomarkers and their clinical validation to the successful market launch of in-vitro diagnostic test kits.

Currently and until 31st March 2011, Oliver serves as CFO of Epigenomics AG (Berlin, Germany, 1999-today) and CEO of Epigenomics, Inc. (Seattle, USA, 2006-today). In these capacities he has been responsible for several private venture capital financings with top-tier VCs, an IPO on the Frankfurt Stock Exchange in 2004, a trans-Atlantic merger including successful postmerger integration, as well as two PIPE financings and two successful public
rights offerings to shareholders in Europe and the USA in the past four years. Over the past twelve years Oliver has raised over 150 million Euros in equity capital for Epigenomics and co-founded a number of other start-up companies.

Oliver also led the corporate and business development teams at Epigenomics in signing strategic R&D collaborations as well as commercialization alliances in molecular diagnostics with partners such as Abbott, Roche, Qiagen, Quest Diagnostics, Sysmex, Philips, ARUP, Warnex as well as forging personalized medicine partnerships with pharmaceutical industry players Astra-Zeneca, J&J, Pfizer, Merck, Amgen and others. In his role as CEO of Epigenomics Inc., Oliver headed a team of up to 40 clinical R&D staff in addition to his commercial functions. Under his leadership Epigenomics Inc. ran a threeyear successful prospective clinical study enrolling almost 8,000 subjects at 32 clinical sites in the U.S. and Germany.

Oliver Schacht earned a diploma in European Business Administration from the European School of Business in Reutlingen and London, as well as a Master’s and Ph.D. degree from the University of Cambridge (UK). During his tenure at Mercer Management Consulting from 1995 to 1999, he worked on projects in M&A, growth strategies and re-organization in pharma, biotech and other sectors.

“We are very pleased that Oliver Schacht has agreed to join the Curetis Team as its CEO in early 2011”, said Frank Mühlenbeck, Chairman of the Supervisory Board. “I am sure the company will benefit greatly from his leadership, expertise and international business background as it moves toward commercialization of its innovative products.”

“I am excited to have the opportunity to join Curetis’ strong management team as the company enters this crucial phase of finalizing the product development, of running pivotal clinical trials and the upcoming market launch of its leading infectious disease platform and first IVD products,” said Oliver Schacht. “I am convinced that the Curetis molecular diagnostic solution is unique, has clear competitive advantages over other approaches, and is poised to become an integral part of routine infectious disease testing. I am particularly excited about the strategic collaboration opportunities and commercial potential of the combination of Curetis’ integrated platform with comprehensive content to address high unmet medical needs.”

Managing Directors Andreas Boos and Johannes Bacher: “We would like to welcome Oliver Schacht as Curetis CEO. Oliver adds vital management, finance and business development skills to our team. We are confident that his long-standing experience with a growth stage company in the molecular diagnostics space will make a significant contribution to Curetis’ future success.”

About Curetis (Germany)

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective tools for diagnosing
severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

Publisher: Curetis AG Dr. Anne Thews, Director Marketing & Sales, Max-Eyth-Straße 42, 71088 Holzgerlingen, Germany, +49 (0) 7031 49195-32,,

Record changed: 2020-04-21


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Oliver Schacht

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top